Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


VUMC Studying Potential Approach to Reverse Precancerous Stomach Lesions


 

Vanderbilt University Medical Center (VUMC) cancer researcher James Goldenring, MD, PhD, has received a two-year, $200,000 grant from the DeGregorio Family Foundation in Pleasantville, New York, to begin clinical trials of a potential approach for reversing precancerous stomach lesions.

Stomach cancer is the fourth leading cause of cancer-related deaths worldwide after lung, liver and colorectal cancers. In the United States, 28,000 people will be diagnosed with stomach cancer this year, and nearly 11,000 will die from the disease, according to the American Cancer Society.

Goldenring said the grant will support an international collaborative trial with colleagues at Yonsei University Medical Center in Seoul, Korea, to test the effectiveness of the drug Selumetinib to reverse pre-cancerous lesions in patients following endoscopic resection of stage I gastric cancer. Koreans have one of the world's highest incidences of gastric cancer.

"I am extremely grateful for the support that we have received from the DeGregorio Family Foundation," said Goldenring, the Paul W. Sanger Professor of Experimental Surgery at Vanderbilt University School of Medicine. "It is often difficult to obtain support for trials that require clinical collaboration at international sites."

Selumetinib blocks MEK, an enzyme downstream of Ras, a signaling protein that regulates cell growth and survival. Abnormal Ras activation, possibly triggered by other signaling molecules, is associated with up to one-third of all human cancers and recently was identified in a large percentage of gastric cancers. A year ago, Goldenring reported in Gastroenterology that Selumetinib, a drug recently approved for use in patients with advanced thyroid cancer, halted and reversed neoplastic progression in a mouse model of activated Ras induction of metaplasia and precancerous lesions in the stomach.

It appears that underneath the abnormal metaplastic cells hides a lineage of normal progenitor cells, which can regenerate the normal mucosal layer of the stomach, Goldenring said. When the consequences of abnormal Ras activation were blocked by Selumetinib, normal cells pushed the abnormal tissue out of the mucosa. The grant will support a study of MEK inhibition in patients who have had local endoscopic removal of a stage I gastric cancer. These patients have a 2 to 5 percent per year incidence of developing a second cancer in the stomach because a large amount of metaplastic mucosa remains.

Astra-Zeneca Corporation will provide the Selumetinib for the trial. Goldenring is professor of Surgery and Cell & Developmental Biology, vice-chair for Surgical Research in the Section of Surgical Sciences and co-director of the Epithelial Biology Center at VUMC. He also is a staff physician at the Veterans Affairs Medical Center (Tennessee Valley Healthcare System, Nashville campus).

 
Share:

Related Articles:


Recent Articles

Clover Health Flu Shot Monitor Finds Only 61% of Nashville Seniors Have Been Immunized This Season

With flu shot rates increasing only 20% over the past month, too many older Middle Tennessee residents remain unvaccinated going into the height of flu season

Read More

Jacobs Out at Acadia

Veteran healthcare CEO Joey Jacobs is out at Acadia Healthcare following a Sunday board meeting that ousted the behavioral health giant's well-known leader.

Read More

Moving beyond Wellness to Well-Being

Increasingly, healthcare providers are expanding their focus beyond physical wellness to take a more holistic view of well-being.

Read More

Seasonal Affective Disorder: The Recurring Winter Blues Storm

In the United States, 10 to 20 percent of people have a form of the winter blues, and about half a million people suffer from winter Seasonal Affective Disorder or SAD.

Read More

Competition Levels Drop in Health Insurance Markets across 25 States

Read More

Vanderbilt Comments on Patient Error, CMS Corrective Action Plan

Following a medication error last December that resulted in a patient death, Vanderbilt University Medical Center faced scrutiny by CMS, which could have potentially impacted Medicare reimbursement. However, on Nov. 29, the federal agency accepted a corrective action plan submitted by the city's academic medical center.

Read More

Lifepoint Health And Rcch Healthcare Partners Announce Completion Of Merger

Read More

Cancer Care on the Cutting Edge

Nashville physician-scientists are helping lead the way in advancing cancer care.

Read More

The Evolution of Senior Living

The senior living industry is undergoing a makeover as baby boomers shift focus from medical-directed care to hospitality-driven services.

Read More

When Basic Science Becomes a Breakthrough

Noted immunologists joined forces at the recent International Cancer Immunotherapy Conference to discuss the importance of fostering and funding basic science.

Read More

Email Print
 
 

 

 


Tags:
cancer research, DeGregorio Family Foundation, grand rounds, James Goldenring, Vanderbilt University Medical Center, VUMC
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: